Sight Sciences, Inc.
SGHT Nasdaq
SEC CIK 1531177
Follow Sight Sciences
Weekly email: filings, results
Revenue, last quarter
$24.9M
+25.2% vs same quarter last year
Net income
−$6.8M
+16.6% vs same quarter last year
EPS, diluted
−$0.12
+25% vs same quarter last year
Operating cash flow
−$2.4M
+72.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $77.4M | −$38.4M |
| FY24 | $79.9M | −$51.5M |
| FY23 | $81.1M | −$55.5M |
| FY22 | $71.3M | −$86.2M |
| FY21 | $49M | −$63M |
| FY20 | $27.6M | −$34.7M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 86.2% | −48% | −49.7% |
| FY24 | 85.5% | −63.3% | −64.5% |
| FY23 | 85.3% | −70.7% | −68.5% |
| FY22 | 82.7% | −117.7% | −120.9% |
| FY21 | 82.4% | −105.2% | −128.6% |
| FY20 | 66.7% | −116.5% | −125.5% |
| FY19 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$29.9M |
| FY24 | −$22.7M |
| FY23 | −$48M |
| FY22 | −$76.9M |
| FY21 | −$53.4M |
| FY20 | −$33.1M |
| FY19 | - |
- Sight Sciences
- Healthcare median
Show the numbers
| Year | Sight Sciences | Healthcare median |
|---|---|---|
| FY25 | −49.7% | −30.6% |
| FY24 | −64.5% | −47% |
| FY23 | −68.5% | −58% |
| FY22 | −120.9% | −80.4% |
| FY21 | −128.6% | −71.8% |
| FY20 | −125.5% | −62.2% |
| FY19 | - | −46.2% |